Viral Vector Formulation and Final Fill

Formulation graphic representing downstream gene therapy processing

Formulating a gene therapy demands a high level of application and regulatory expertise. Viral vectors are subject to variations in process and in therapy dosages ruling out a one-size-fits-all approach. To minimize risk, gene therapies must be formulated to meet unique regulatory requirements, and deliver reproducible product quality, safety, yield, titer, and purity.

Throughout the formulation process, manufacturers must leverage application expertise, state-of-the-art production facilities, and regulatory knowledge that can be costly and time-consuming to develop in-house. Selecting a strong and experienced partner is a decision of critical importance, simplifying the complexity of supplier qualification and speeding up processes to reduce the total cost of ownership.


Gene Therapy Manufacturing

Gene Therapy Manufacturing

The rise of gene therapies is driving rapid innovation, but manufacturers face complex challenges bringing new therapies to life

Viral Vector Upstream Processing

Making the right upstream process decisions not only impacts viral vector titer, but downstream processes, timelines, and regulatory acceptance

Viral Vector Downstream Processing

Efficient virus purification processes can improve yield, decrease time to patient, and lower manufacturing costs

Viral Vector Characterization and Biosafety Testing

Critical biosafety testing and characterization of viral vector products can help to fully analyze key quality attributes: identity, potency, safety, and stability

Viral Vector Contract Development and Manufacturing

CDMO partnerships play a critical role in advancing clinical pipelines and achieving successful commercialization